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Following 28 days, coronary angiography was performed, animals
sacriﬁced and stented segments harvested for histopathological
evaluation.
RESULTS In angiography at 28 days, the late lumen loss was lowest in
the elevated dose SES (ed-frSES: 0.200.2 vs. frSES 0.800.5 vs. BMS:
0.960,50.5 mm, p<0,01). This was conﬁrmed in the morphometric
evaluation in histopathology as represented by signiﬁcant and dose
dependent decrease in percent area stenosis (ed-frSES: 22.412.7% vs.
frSES: 3510.7% vs. BMS: 47.512.5%; p<0,01). There was no peri-
strut inﬂammation in any of the groups. Endothelialisation score was
numerically, however not meaningfully decreased in ed-frSES (ed-
frSES: 2.93 vs. 3. vs. 3; p¼0,05). Signs of ﬁbrin were also noted in ed-
frSES (ed-frSES: 0,4 vs. frSES: 0 vs. BMS: 0, p¼0,05).
CONCLUSIONS Sirolimus dose dependent vascular response was re-
ported. The elevated dose, fast releasing SES shows satisfactory
vascular healing, similar to regular dose, fast release SES, with
improved efﬁcacy in restenosis inhibition.
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BACKGROUND Percutaneous coronary intervention (PCI) of coronary
calciﬁed lesions has been associated with worse clinical outcomes
compared to non-calciﬁed lesions. However, the impact of coronary
calciﬁcations (CC) two years after drug-eluting stent (DES) PCI is un-
known. We sought to evaluate the frequency and impact of CC two
years after DES PCI from the large ADAPT-DES registry.
METHODS ADAPT-DES was a prospective, multicenter “all-comers”
registry of consecutive patients successfully treated with at least one
DES. Two-year outcomes were analyzed according to the presence of
CC as assessed by the enrolling site operator.
RESULTS A total of 8,578 patients underwent DES PCI; CC of at least
one target lesion was present in 2,646 patients (30.8%). Patients with
CC were older, more frequently had diabetes, hypertension, dyslipi-
demia, renal insufﬁciency, left main or LAD disease, and multivessel
intervention, with more stents implanted. IVUS was used equally in
both groups. Second-generation DES were implanted less frequently
among patients with CC (60.5% vs. 64.7%, p¼0.0002). At two years,
CC patients had higher unadjusted rates of adverse ischemic and
bleeding events (Table). By multivariable analysis, the presence of CC
was a strong independent predictor of death (HR [95%CI] ¼ 4.92 [1.29,
18.80], myocardial infarction (HR [95%CI] ¼ 1.67 [1.26-2.23],p¼0.0004), MACE (HR [95%CI] ¼ 1.82 [1.37, 2.41], p<0.0001 and major
bleeding (HR [95%CI] ¼ 1.76 [1.44-2.16], p<0.0001).Calciﬁed lesions
(N[2,646)Non-calciﬁed lesions
(N[5,932) P-valueAll-cause death 4.8% (124) 3.5% (192) 0.003Cardiovascular 2.8% (73) 2.3% (124) 0.09Non-cardiovascular 2.0% (51) 1.2% (68) 0.008Myocardial infarction 6.4% (135) 4.0% (226) <0.0001ST deﬁnite/probable 1.2% (30) 1.1% (63) 0.82Any revascularization 21.7% (574) 19.7% (1167) 0.03Clinically-driven
TVR10.0% (264) 8.8% (525) 0.09Clinically-driven TLR 5.8% (153) 5.4% (322) 0.50Target vessel failure 18.2% (471) 14.2% (801) <0.0001MACE* 12.8% (329) 9.9% (556) <0.0001Major bleeding 14.0% (370) 6.2% (369) <0.0001Values are Kaplan-Meier estimates presented as % (n). TVR ¼ target vessel revascularization; ST ¼ stent
thrombosis; TLR ¼ target lesion revascularization; *MACE ¼ major adverse cardiovascular events, deﬁned as
the composite of cardiac death, myocardial infarction, or ischemia-driven target lesion revascularization;
target vessel failure ¼ the composite of cardiac death, target vessel revascularization, and MI.
CONCLUSIONS Target lesion CC as assessed by the interventionalist
is relatively frequent, being present in approximately one-third of
patients undergoing PCI. CCA was strongly predictive of adverse
ischemic and bleeding events 2 years after DES PCI.
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BACKGROUND Multiple coronary artery disease (CAD) including diabetic
patients (pts) remained a challenge for percutaneous coronary in-
terventions (PCI). Introduction of newer generation of drug eluting stent
(DES) signiﬁcantly improved safety and efﬁcacy compared with the pre-
vious ones although its value in pts with complex CAD in comparison with
1st generation DES is not established yet.
METHODS From March 2013 to February 2014, 225 pts with complex
CAD undergoing DES implantation in 15 centers in Argentina were
prospectively included. The registry was approved by local regula-
tory authorities and monitored by an independent safety committee.
Primary endpoint was to assess the incidence of major adverse car-
diovascular events (MACCE) deﬁned as death, myocardial infarction
(MI) stroke and unplanned new revascularization (TVR) using Fire-
bird-2 (2nd generation chromo-cobalt rapamycin eluting stent,
Microport Medical Co, Shanghai) vs. ERACI III population (DES arm)
at long term follow-up. Inclusion criteria were indication of
myocardial revascularization in 2, 3 major coronary arteries and/or
unprotected left main disease (ULMD). Exclusion criteria were poor
ejection fraction (<35%), recent ST elevation MI, previous DES,
lesion diameter < 2.5 mm, renal failure and contraindications for
dual antiplatelet therapy (DAPT). Stent thrombosis was analyzed. All
revascularization was done by intention-to-treat-principle and op-
erator’s advice was to treat only lesions  70% of diameter stenosis
in vessels with, at least, 2.0 mm of reference diameter, to fulﬁll a
modiﬁed in SYTNAX score. In ERACI IV the only DES allowed was
Firebird-2, whereas in ERACI III 1st DES generation was used. All
patients received DAPT for one year.
RESULTS Mean age of the 225 pts was 64.5 þ/- 11.0 years, with 30.6%
diabetics and 67.7% with 3 vessels or ULMD. Modiﬁed SYNTAX score
was 22 þ/- 11 and we implanted 1.7 þ/- 1.8 Firebird-2 per patient,
similar to the ERACI III DES arm (1.79), p¼0.8. Stent length was
41.4 mm þ/- 10.8 vs 36.1 mm þ/- 8.9 in ERACI IV and ERACI III,
